Asset 2 Conferences
Carr Steven - profile picture

Steven Carr

Broad Institute of MIT and Harvard, US

Steven Carr is Director of Proteomics at the Broad Institute of MIT and Harvard. He is internationally recognized as a leader in the development of novel proteomics methods and in their application in biology and medicine.

Steve and his group collaborate with scientists throughout the Broad Institute community (Harvard University, Harvard Medical School, and the 17 Harvard-affiliated hospitals) to apply state-of-the-art proteomics technology to address compelling questions in biology, chemistry, and clinical medicine. Research in his lab focuses on detecting and quantifying post-translational modifications (e.g., phosphorylation, acetylation, ubiquitylation, methylation, etc.) in the proteome, developing new technologies to quantify proteins in cells and biofluids with high sensitivity and specificity, improving informatics for peptide and protein assignment using mass spectrometry (MS) data, and integrating MS-derived data with genomic data. The Carr group is also known for developing and applying systematic approaches for biomarker discovery and validation to ultimately provide biomarkers for cancers, heart disease, infectious diseases, and metabolic disorders. He has over 225 publications on the development and use of proteomics and biological mass spectrometry.

Prior to joining the Broad Institute in 2004, Steve held scientific leadership positions in the pharmaceutical and biotechnology industries, including GlaxoSmithKline and Millennium. Steve is the recipient of a number of awards, including the 2011 Discovery Award in Proteomics from the Human Proteome Organization, the 2011 Thought Leader Award in Proteomics from the Agilent Foundation, and the 2014 Wallace H. Coulter Lectureship Award.